AUG 13, 2026 · PHASE 1 TRIAL
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
ClinicalTrials.gov
This is a Phase 1, open-label dose escalation study in early recruitment that has not yet posted results; it represents first-in-human work designed to characterize safety and tolerability.
Reported
Planned sample size18
Study phasePhase 1
Primary outcome duration52 weeks